IBDEI0M5 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10505,2)
 ;;=^11141
 ;;^UTILITY(U,$J,358.3,10506,0)
 ;;=367.0^^44^566^31
 ;;^UTILITY(U,$J,358.3,10506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10506,1,3,0)
 ;;=3^Hypermetropia
 ;;^UTILITY(U,$J,358.3,10506,1,4,0)
 ;;=4^367.0
 ;;^UTILITY(U,$J,358.3,10506,2)
 ;;=^60139
 ;;^UTILITY(U,$J,358.3,10507,0)
 ;;=367.1^^44^566^37
 ;;^UTILITY(U,$J,358.3,10507,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10507,1,3,0)
 ;;=3^Myopia
 ;;^UTILITY(U,$J,358.3,10507,1,4,0)
 ;;=4^367.1
 ;;^UTILITY(U,$J,358.3,10507,2)
 ;;=^80671
 ;;^UTILITY(U,$J,358.3,10508,0)
 ;;=V43.1^^44^566^45
 ;;^UTILITY(U,$J,358.3,10508,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10508,1,3,0)
 ;;=3^Pseudophakia
 ;;^UTILITY(U,$J,358.3,10508,1,4,0)
 ;;=4^V43.1
 ;;^UTILITY(U,$J,358.3,10508,2)
 ;;=^69114
 ;;^UTILITY(U,$J,358.3,10509,0)
 ;;=367.9^^44^566^46
 ;;^UTILITY(U,$J,358.3,10509,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10509,1,3,0)
 ;;=3^Refractive Error
 ;;^UTILITY(U,$J,358.3,10509,1,4,0)
 ;;=4^367.9
 ;;^UTILITY(U,$J,358.3,10509,2)
 ;;=^35634
 ;;^UTILITY(U,$J,358.3,10510,0)
 ;;=365.04^^44^566^26
 ;;^UTILITY(U,$J,358.3,10510,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10510,1,3,0)
 ;;=3^Glaucoma Ocular Hypertension
 ;;^UTILITY(U,$J,358.3,10510,1,4,0)
 ;;=4^365.04
 ;;^UTILITY(U,$J,358.3,10510,2)
 ;;=^85124
 ;;^UTILITY(U,$J,358.3,10511,0)
 ;;=365.01^^44^566^30
 ;;^UTILITY(U,$J,358.3,10511,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10511,1,3,0)
 ;;=3^Glaucoma Suspect
 ;;^UTILITY(U,$J,358.3,10511,1,4,0)
 ;;=4^365.01
 ;;^UTILITY(U,$J,358.3,10511,2)
 ;;=^340633
 ;;^UTILITY(U,$J,358.3,10512,0)
 ;;=365.71^^44^566^24
 ;;^UTILITY(U,$J,358.3,10512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10512,1,3,0)
 ;;=3^Glaucoma Mild Stage
 ;;^UTILITY(U,$J,358.3,10512,1,4,0)
 ;;=4^365.71
 ;;^UTILITY(U,$J,358.3,10512,2)
 ;;=^340513
 ;;^UTILITY(U,$J,358.3,10513,0)
 ;;=365.72^^44^566^25
 ;;^UTILITY(U,$J,358.3,10513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10513,1,3,0)
 ;;=3^Glaucoma Moderate Stage
 ;;^UTILITY(U,$J,358.3,10513,1,4,0)
 ;;=4^365.72
 ;;^UTILITY(U,$J,358.3,10513,2)
 ;;=^340514
 ;;^UTILITY(U,$J,358.3,10514,0)
 ;;=365.73^^44^566^28
 ;;^UTILITY(U,$J,358.3,10514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10514,1,3,0)
 ;;=3^Glaucoma Severe Stage
 ;;^UTILITY(U,$J,358.3,10514,1,4,0)
 ;;=4^365.73
 ;;^UTILITY(U,$J,358.3,10514,2)
 ;;=^340515
 ;;^UTILITY(U,$J,358.3,10515,0)
 ;;=362.51^^44^566^1
 ;;^UTILITY(U,$J,358.3,10515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10515,1,3,0)
 ;;=3^AMD,Dry
 ;;^UTILITY(U,$J,358.3,10515,1,4,0)
 ;;=4^362.51
 ;;^UTILITY(U,$J,358.3,10515,2)
 ;;=^268636
 ;;^UTILITY(U,$J,358.3,10516,0)
 ;;=362.52^^44^566^2
 ;;^UTILITY(U,$J,358.3,10516,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10516,1,3,0)
 ;;=3^AMD,Wet/Exudative
 ;;^UTILITY(U,$J,358.3,10516,1,4,0)
 ;;=4^362.52
 ;;^UTILITY(U,$J,358.3,10516,2)
 ;;=^268637
 ;;^UTILITY(U,$J,358.3,10517,0)
 ;;=362.04^^44^566^14
 ;;^UTILITY(U,$J,358.3,10517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10517,1,3,0)
 ;;=3^DM Mild NPDR
 ;;^UTILITY(U,$J,358.3,10517,1,4,0)
 ;;=4^362.04
 ;;^UTILITY(U,$J,358.3,10517,2)
 ;;=^332787
 ;;^UTILITY(U,$J,358.3,10518,0)
 ;;=362.05^^44^566^15
 ;;^UTILITY(U,$J,358.3,10518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10518,1,3,0)
 ;;=3^DM Moderate NPDR
 ;;^UTILITY(U,$J,358.3,10518,1,4,0)
 ;;=4^362.05
 ;;^UTILITY(U,$J,358.3,10518,2)
 ;;=^332788
 ;;^UTILITY(U,$J,358.3,10519,0)
 ;;=362.06^^44^566^17
 ;;^UTILITY(U,$J,358.3,10519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10519,1,3,0)
 ;;=3^DM Severe NPDR
 ;;^UTILITY(U,$J,358.3,10519,1,4,0)
 ;;=4^362.06
 ;;
 ;;$END ROU IBDEI0M5
